On Monday, pharmaceutical giant Sun Pharma said it had completed its acquisition of US-based Concert Pharmaceuticals.

In January, the Mumbai-based company signed a deal to acquire Concert for $576 million.

Sun Pharma said in a regulatory filing that the pharmaceuticals major has successfully acquired Concert Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company developing deuruxolitinib as a potential treatment for adult patients with moderate to severe alopecia areata.

Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry.